Neuroscience
Steering Committee

The Biomarkers Consortium’s Cancer, Inflammation and Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by the Biomarkers Consortium, as well as overseeing each individual project under its purview. The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.

Linda Brady, Ph.D., NIH/NIMH (Co-Chair)

Penny Dacks, Ph.D., Association for Frontotemporal Degeneration (Co-Chair)

Danielle Graham, Ph.D., Biogen (Co-Chair)

William Potter, M.D., Ph.D., (Co-Chair Emeritus)

Marc Aafjes, M.B.A., Deliberate AI

Alexandre Akoulitchev, Ph.D., Oxford Biodynamics

Muneer Ali, M.D., Tempus

Anthony Bannon, Ph.D., AbbVie

Richard Batrla, M.D., Ph.D., SunBird Bio

Anna Berdine, Alamar Bio

Wade Berrettini, M.D., Ph.D., UPenn

Diane Bovenkamp, Ph.D., BrightFocus Foundation

Mark Brody, Ph.D., Evolution Research Group

Xuemei Cai, M.D., Pfizer

Maria Carrillo, Ph.D., Alzheimer’s Association®

Emily Collins, Ph.D., Eli Lilly

Nicole Davis, Ph.D., Ultragenyx

Francesca DeSimone, Ph.D., Fujirebio US

Ken Duckworth, M.D., National Alliance on Mental Illness

John Dwyer, J.D., Global Alzheimer’s Platform Foundation

Lorna Farrelly, Ph.D., Regeneron

Thomas Finn, Ph.D., FDA/CBER

Bernard Fischer, M.D., FDA/CDER

Mariana Fontes, Ph.D., Olink Proteomics

Tim Hammond, Ph.D., Sanofi

Glenn A. Harris, Ph.D.,  Rainwater Charitable Foundation

Robert Iannone, M.D., Jazz Pharmaceuticals

Morten Karsdal, Ph.D., Nordic Bioscience

Showkhin Khan, Ultragenyx

Katherine Jung, Ph.D., NIH/NIAAA

Hartmuth Kolb, Ph.D., Enigma Biomedical Group

Walter Koroshetz, M.D., NIH/NINDS

Walter Kostich, Ph.D., National MS Society, Inc.

Frank Lebeda, Ph.D., US Military

 

Tara Lincoln, MLIS, The Robert Packard Center for ALS Research at Johns Hopkins

Andrew Lowe, MSD

Miroslaw Mackiewicz, Ph.D., NIH/NIA

David Millis, M.D., M.B.A., Ph.D., FDA/CDER

Larry Mimms, Ph.D., Schizophrenia & Psychosis Action Alliance

Satoshi Minoshima, M.D., Ph.D., Radiological Society of North America

Laura Mitic, Ph.D., The Bluefield Project to Cure FTD

Mike Montalto, Ph.D., Path AI

Mario Morken, Sunbird Bio

Andrea Mortera, Empatica

Sze-Ling Ng, Ph.D., GSK

Laura Nisenbaum, Ph.D., Alzheimer’s Drug Discovery Foundation

Dimitry Ofengeim, Ph.D., Sanofi

Lovingly Park, Ph.D., Alector

Mary Ann Pelleymounter, Ph.D., NIH/NINDS

Christos Petropoulos, Ph.D., LabCorp

Brooke Rhead, Ph.D., Tempus

Ziad Saad, Ph.D. , Johnson & Johnson

Mert Sahin, Ph.D., Durin Technologies

Steve Sands, Ph.D., Amgen

Swati Sathe, M.D., CHDI Foundation

Daniel Smith, Ph.D., Alkermes

Gad Soffer, M.S., General Metabolics

Joyce Suhy, Ph.D., Clario

Aishu Sukumar, M.Phil., M.P.H., Gates Ventures

Johannes Tauscher, M.D., Takeda

Ina Tesseur, Ph.D., UCB Biopharma SPRL

Chris Turck, Ph.D., Max Planck Institute of Psychiatry

Eugeen Vanmechelen, Ph.D., ADx NeuroSciences

Philip Verghese, Ph.D., C2N Diagnostics

Shidong Wang, Standard BioTools

Christopher Weber, Ph.D., Alzheimer’s Association®

Joel Wommack , Ph.D., Standard Biotools

Henrik Zetterberg, M.D., Ph.D., University of Gothenburg